Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Real-world, Prospective, Multicenter Study of Safety and Effectiveness of Xolair (Omalizumab) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Chinese Adolescents Inadequately Controlled With H1 Antihistamines

Next Previous
Trial Profile

A Real-world, Prospective, Multicenter Study of Safety and Effectiveness of Xolair (Omalizumab) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Chinese Adolescents Inadequately Controlled With H1 Antihistamines

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Chronic urticaria
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 14 Jan 2025 Planned End Date changed from 30 Dec 2027 to 1 Oct 2025.
  • 14 Jan 2025 Planned primary completion date changed from 30 Dec 2027 to 1 Oct 2025.
  • 06 Mar 2024 Planned End Date changed from 31 Mar 2025 to 30 Dec 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top